Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help...

Full description

Bibliographic Details
Main Authors: Pengfei Jin, Jingxin Li, Hongxing Pan, Yanfei Wu, Fengcai Zhu
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Signal Transduction and Targeted Therapy
Online Access:https://doi.org/10.1038/s41392-021-00481-y
id doaj-6edd55c8f36942b59c9affe4bb91ece4
record_format Article
spelling doaj-6edd55c8f36942b59c9affe4bb91ece42021-02-07T12:19:56ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352021-02-01611610.1038/s41392-021-00481-yImmunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we needPengfei Jin0Jingxin Li1Hongxing Pan2Yanfei Wu3Fengcai Zhu4Department of Vaccine Clinical Evaluation, Jiangsu Province Center for Disease Control and PreventionDepartment of Vaccine Clinical Evaluation, Jiangsu Province Center for Disease Control and PreventionDepartment of Vaccine Clinical Evaluation, Jiangsu Province Center for Disease Control and PreventionDepartment of Epidemiology and Biostatistics, School of Public Health, Southeast UniversityDepartment of Vaccine Clinical Evaluation, Jiangsu Province Center for Disease Control and PreventionAbstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.https://doi.org/10.1038/s41392-021-00481-y
collection DOAJ
language English
format Article
sources DOAJ
author Pengfei Jin
Jingxin Li
Hongxing Pan
Yanfei Wu
Fengcai Zhu
spellingShingle Pengfei Jin
Jingxin Li
Hongxing Pan
Yanfei Wu
Fengcai Zhu
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
Signal Transduction and Targeted Therapy
author_facet Pengfei Jin
Jingxin Li
Hongxing Pan
Yanfei Wu
Fengcai Zhu
author_sort Pengfei Jin
title Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_short Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_full Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_fullStr Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_full_unstemmed Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
title_sort immunological surrogate endpoints of covid-2019 vaccines: the evidence we have versus the evidence we need
publisher Nature Publishing Group
series Signal Transduction and Targeted Therapy
issn 2059-3635
publishDate 2021-02-01
description Abstract In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are under way, which provide opportunities for the determination of COVID-19 correlates of protection. In this paper, we review current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlates of protection and issues related to COVID-19 correlates of protection.
url https://doi.org/10.1038/s41392-021-00481-y
work_keys_str_mv AT pengfeijin immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT jingxinli immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT hongxingpan immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT yanfeiwu immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
AT fengcaizhu immunologicalsurrogateendpointsofcovid2019vaccinestheevidencewehaveversustheevidenceweneed
_version_ 1724281340582428672

Similar Items